Graft-vs-Host Disease (GVHD) — Deal Benchmarks & Valuation
Market Analysis
Graft-vs-Host Disease (GVHD) is one of the most actively transacted indications in immunology licensing. Phase 1 deals for graft-vs-host disease (gvhd) carry a median total deal value of $3.5B, with upfront payments ranging from $160M to $560M. The recommended deal structure allocates approximately 10% to upfront payments and 90% to milestones.
Milestone structures for graft-vs-host disease (gvhd) deals allocate $1.1B to development milestones, $1.1B to regulatory milestones, and $931M to commercial milestones. Royalty rates range from 11.8% to 20.6% at the base tier, with tiered escalation reaching 15.8%-24.6% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for graft-vs-host disease (gvhd) licensing?
What royalty rates are standard for graft-vs-host disease (gvhd) deals?
How are graft-vs-host disease (gvhd) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.